---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-033367"
form_type: "8-K"
ticker: "TRAW"
cik: "0001130598"
company_name: "Traws Pharma, Inc."
filed_at: "2023-03-16T23:59:59+00:00"
generated_at: "2026-06-18T00:10:44.505110+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Onconova full-year net loss $19.0M; cash $38.8M into Q1 2024

## Summary
- Net loss $19.0M ($0.91 loss per share) vs $16.2M ($0.96 loss per share) in 2021 on higher shares outstanding.
- Cash and equivalents $38.8M at Dec 31, 2022, down from $55.1M; cash runway into Q1 2024.
- R&D expenses rose to $11.4M from $7.3M, driven by narazaciclib development and manufacturing.
- Narazaciclib Phase 1 advancing to 240 mg continuous daily cohort; LGEEC trial opening Q1 2023, data Q4 2023.
- Two complete responses in RDEB-associated SCC with rigosertib; plan to discuss regulatory path with agencies.

## SEC filing metadata
- accession: 0001104659-23-033367
- form_type: 8-K
- ticker: TRAW
- cik: 0001130598
- company_name: Traws Pharma, Inc.
- filed_at: 2023-03-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130598/000110465923033367/0001104659-23-033367-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130598/000110465923033367/tm239793d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-033367
- JSON: https://secwatch.observer/filing/0001104659-23-033367.json
- Plain text: https://secwatch.observer/filing/0001104659-23-033367.txt

## Key facts
- Earnings Releases
  Traws Pharma, Inc. reported the twelve months ended December 31, 2022 results: net income $19.0 million, EPS $0.91 per share.
  - Period: the twelve months ended December 31, 2022
  - Net income: $19.0 million
  - EPS: $0.91 per share
  - Result: reported results
  source text: Net loss for 2022 was $19.0 million, or $0.91 per share on 20.9 million weighted average shares outstanding, compared with a net loss of $16.2 million, or $0.96 per share for 2021 based on 16.8 million weighted average shares outstanding.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1130598/000110465923033367/0001104659-23-033367-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.